KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables (2016 - 2022)

Historic Receivables for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2022 value amounting to $32.2 million.

  • TherapeuticsMD's Receivables fell 1402.33% to $32.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $32.2 million, marking a year-over-year decrease of 1402.33%. This contributed to the annual value of $36.2 million for FY2021, which is 1171.64% up from last year.
  • According to the latest figures from Q3 2022, TherapeuticsMD's Receivables is $32.2 million, which was down 1402.33% from $45.8 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Receivables peaked at $45.8 million during Q2 2022, and registered a low of $5.1 million during Q1 2018.
  • Over the past 5 years, TherapeuticsMD's median Receivables value was $24.1 million (recorded in 2020), while the average stood at $24.1 million.
  • As far as peak fluctuations go, TherapeuticsMD's Receivables soared by 22675.18% in 2019, and later tumbled by 1402.33% in 2022.
  • Over the past 5 years, TherapeuticsMD's Receivables (Quarter) stood at $11.1 million in 2018, then surged by 120.5% to $24.4 million in 2019, then soared by 32.74% to $32.4 million in 2020, then increased by 11.72% to $36.2 million in 2021, then fell by 11.11% to $32.2 million in 2022.
  • Its Receivables stands at $32.2 million for Q3 2022, versus $45.8 million for Q2 2022 and $35.4 million for Q1 2022.